What is HC Wainwright’s Forecast for PVLA Q1 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – HC Wainwright issued their Q1 2027 EPS estimates for Palvella Therapeutics in a report issued on Monday, October 12th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($2.40) for the quarter. HC Wainwright has a “Buy” rating and a $246.00 price target on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($6.40) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q2 2027 earnings at ($2.59) EPS, Q3 2027 earnings at ($4.16) EPS and Q4 2027 earnings at ($4.36) EPS.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35).

A number of other analysts also recently weighed in on PVLA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Chardan Capital initiated coverage on shares of Palvella Therapeutics in a research note on Monday, September 21st. They issued a “buy” rating and a $240.00 price objective on the stock. Finally, Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $207.43.

Palvella Therapeutics Price Performance

PVLA opened at $122.58 on Thursday. Palvella Therapeutics has a 52-week low of $68.96 and a 52-week high of $161.38. The business’s fifty day moving average is $146.74 and its 200-day moving average is $134.32.

Hedge Funds Weigh In On Palvella Therapeutics

Large investors have recently bought and sold shares of the company. KBC Group NV acquired a new stake in shares of Palvella Therapeutics during the first quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Palvella Therapeutics during the second quarter worth about $35,000. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics during the second quarter worth about $69,000. Quantbot Technologies LP acquired a new position in shares of Palvella Therapeutics in the second quarter valued at approximately $71,000. Finally, State of Wyoming acquired a new position in shares of Palvella Therapeutics in the second quarter valued at approximately $134,000. 40.11% of the stock is currently owned by institutional investors.

Insider Transactions at Palvella Therapeutics

In other news, Director Christopher Kiritsy sold 313 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the transaction, the director directly owned 250 shares in the company, valued at approximately $39,250. This represents a 55.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total value of $654,807.42. Following the completion of the transaction, the chief operating officer owned 2,154 shares of the company’s stock, valued at $327,860.34. The trade was a 66.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 56,743 shares of company stock worth $8,219,632. Corporate insiders own 17.20% of the company’s stock.

Trending Headlines about Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $246 price target. Although the firm lowered its earnings estimates, the target remains well above recent trading levels, reflecting continued confidence in Palvella’s longer-term opportunity. Palvella Therapeutics analyst coverage
• Neutral Sentiment: Palvella will present at the Chardan 10th Annual Healthcare Conference on October 20. Management’s fireside chat may provide updates on QTORIN 3.9% and the company’s rare-disease programs, but the announcement contained no new clinical or regulatory information. Palvella conference announcement
• Negative Sentiment: HC Wainwright substantially reduced its 2027–2030 EPS forecasts. Estimates now call for losses of $13.52 per share in 2027, $10.40 in 2028 and $4.84 in 2029. The 2030 profit estimate was cut to $5.82 from $19.10. The revisions imply a slower path to profitability and are the clearest fundamental pressure on PVLA.
• Negative Sentiment: Director George Jenkins sold 20,326 shares for approximately $2.69 million. The sales on October 12 and 13 reduced his direct position by roughly 13%. Both transactions were executed under a pre-arranged Rule 10b5-1 plan, which reduces their signaling value, but the size of the sales may still weigh on sentiment. Palvella SEC insider transaction filing

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.